SCHEMBL5465852

SCHEMBL5465852

O=c1[nH]nc2ccc3cccc(O)c3n12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 8/20 0.38
CDK2 P24941 2/20 0.38
AURKA O14965 1/20 0.37
PDE5A O76074 3/20 0.35
PDE1A P54750 3/20 0.35
PDE1B Q01064 3/20 0.35
PDE3B Q13370 3/20 0.35
PDE1C Q14123 3/20 0.35
PDE3A Q14432 3/20 0.35
NOTUM Q6P988 3/20 0.35
KDM4E B2RXH2 2/20 0.33
KMT2A Q03164 2/20 0.33
MEN1 O00255 1/20 0.33
INPPL1 O15357 1/20 0.33
NSD2 O96028 1/20 0.33
ALDH1A1 P00352 1/20 0.33
TP53 P04637 1/20 0.33
POLB P06746 1/20 0.33
CYP3A4 P08684 1/20 0.33
GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1602164 0.75 CHEK1 (0.54) CHEK1PDE5APDE1APDE1BPDE3B
SCHEMBL13114979 0.67 CHEK1 (0.43) CHEK1PDE5APDE1APDE1BPDE3B
SCHEMBL18632532 0.67 CHEK1 (0.43) CHEK1PDE5APDE1APDE1BPDE3B
SCHEMBL5766913 0.66 PARP15 (0.42) CDK2KDM4EKMT2AMEN1ALDH1A1
SCHEMBL5470280 0.66 CHEK1 (0.67) CHEK1
SCHEMBL5475521 0.64 CHEK1 (0.52) CHEK1NOTUM
SCHEMBL3107572 0.63 MAPT (0.50) CDK2KDM4EKMT2AMEN1INPPL1
SCHEMBL18632524 0.63 PDE3B (0.47) CHEK1AURKAPDE5APDE1APDE1B
SCHEMBL17403218 0.63 CHEK1 (0.42) CHEK1PDE5APDE1APDE1BPDE3B
SCHEMBL19646489 0.63 CHEK1 (0.42) CHEK1PDE5APDE1APDE1BPDE3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070149560-A1 Novel fused triazolones and the uses thereof ASTRAZENECA AB (SE) 2007-06-28 US claimed
US-20070149560-A1 Novel fused triazolones and the uses thereof ASTRAZENECA AB (SE) 2007-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149560-A1 Novel fused triazolones and the uses thereof TP53, BRCA1, KLK3 CHEK1 13/4885CDK2 254/4885AURKA 484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.